SynAct Pharma AB Stock

SYNACT

SE0008241491

Pharmaceuticals

Market Closed - Nasdaq Stockholm 12:00:00 2026-10-21 EDT			5-day change	1st Jan Change
17.44 ^SEK	+1.63%		+1.40%	-22.83%

09-16	Synact Pharma's resomelagon highlighted by WHO for dengue fever	FW
09-16	SynAct Pharma Identifies Resomelagon As One Of Six Dengue Drug Candidates With Evidence Supporting Further Clinical Development	CI

Last Transcript: SynAct Pharma AB

SynAct Pharma AB - Special Call

06-15

More transcripts

Analysts' recommendations: SynAct Pharma AB

06-18	Edison Maintains Its Valuation for Synact Pharma After Trial Results	FW
03-04	Edison Raises Valuation of Synact Pharma - Commissioned Analysis	FW
02-09	Redeye Raises Target Price for Synact Pharma to 31 Kronor (26)	FW
25-10-31	Redeye Raises Target Price for Synact Pharma to 26 Kronor (25)	FW
25-10-28	Edison Initiates Coverage of Synact Pharma, Assigns Value of SEK 36.9 Per Share	FW

More recommendations

Press Releases: SynAct Pharma AB

09-22	SynAct Pharma to participate in investor and partnering conferences	AQ
09-16	WHO identifies resomelagon as one of six dengue drug candidates with evidence supporting further clinical development	AQ
09-10	SynAct Pharma to Present at Investing in Life Science on September 22	AQ
09-08	SynAct Pharma : Bolagspresentation September 2026	PU
09-08	SynAct Pharma : Company presentation	PU

More press releases

Managers and Directors: SynAct Pharma AB

Manager	Title	Age	Since
Jeppe Øvlesen CEO	Chief Executive Officer	64	2013-12-31
Ann Kristin Led DFI	Director of Finance/CFO	-	2026-02-28
Kirsten Harting CTO	Chief Tech/Sci/R&D Officer	-	2024-02-14

Director	Title	Age	Since
Jeppe Øvlesen BRD	Director/Board Member	64	2024-03-19
Anders Kronborg CHM	Chairman	62	2024-03-19
Sten Scheibye BRD	Director/Board Member	75	2024-03-19

More insiders

SynAct Pharma AB is a manufacturer of biological products. The Company is located in Lund, Sweden. It develops medicines for acute impairment in inflammatory diseases. The company's drug candidate AP1189 is intended for the treatment of arthritis including psoriasis arthritis.

Employees

Sector

Pharmaceuticals

Calendar

11-01 Earnings release - Q3 2026

More about the company

Quotes

Date	Price	Change	Volume
26-10-21	SEK 17.44	+1.63%	37,888
26-10-20	SEK 17.16	+1.30%	62,065
26-10-19	SEK 16.94	-0.35%	72,990
26-10-16	SEK 17.00	+0.24%	34,266
26-10-15	SEK 16.96	-0.24%	38,380

Delayed Quote Nasdaq Stockholm

More quotes

EPS Estimates

Evolution of Analysts' Estimates - EPS - SynAct Pharma AB

Revisions to estimates

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - SynAct Pharma AB

Company calendar

Market Cap	977M 98.73M 87.98M 81.45M 73.71M 139M 9.32B 141M 383M 4.9B 370M 363M 15.61B	P/E 2026 *	-10.4x	P/E 2027 *	-17.8x
Enterprise Value	1B 101M 90.21M 83.52M 75.59M 142M 9.55B 144M 393M 5.02B 380M 372M 16B	EV / Sales 2026 *	22.6x	EV / Sales 2027 *	48.6x
Free-Float	74.7%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Nasdaq Stockholm	SYNACT	Delayed
CBOE		Real-time
Deutsche Boerse AG	8F8	Delayed
Börse Stuttgart	8F8	Delayed
CBOE		Real-time
Tradegate	8F8	Real-time
Boerse Muenchen	8F8	Real-time

09-16	Synact Pharma's resomelagon highlighted by WHO for dengue fever	FW
09-16	SynAct Pharma Identifies Resomelagon As One Of Six Dengue Drug Candidates With Evidence Supporting Further Clinical Development	CI
09-07	Synact surged in Stockholm, the OMXS30 index rose 0.2 percent	FW
09-07	Rejlers slides on merger plans, OMXS30 index up 0.3 percent	FW
09-07	Synact Pharma sees support for phase 3 after post hoc analysis	FW
09-07	SynAct Pharma AB Announces Further Analysis Of Phase 2b ADVANCE Study And Supports Phase 3 Development For Resomelagon	CI
09-03	Stockholm stocks rise, Clas Ohlson jumps on earnings, OMXS30 index up 0.6 percent	FW
09-03	Synact Pharma CEO and head of research sell shares for tax reasons	FW
08-28	Synact Pharma to present new preclinical data for resomelagon at WCI	FW
08-28	SynAct Pharma Presents New Resomelagon Preclinical Data On Phase 3-Ready Ra Therapeutic Candidate At The 17th World Congress Of Inflammation 2026	CI
08-20	SynAct Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-20	Synact Pharma reports narrower operating loss	FW
08-20	Calendar Thursday, August 20	FW

1 day	+1.63%
1 week	+1.40%
Current month	-0.34%
1 month	-2.90%
3 months	-6.24%
6 months	+1.63%
Current year	-22.83%

1 week	16.24	17.7
1 month	16.24	18.28
Current year	7.05	24.4
1 year	7.05	24.6
3 years	4.98	25.3
5 years	4.98	146
10 years	4.8	146

SynAct Pharma AB Stock

Stocks

SYNACT

SE0008241491

Pharmaceuticals

Valuation: SynAct Pharma AB

Chart: SynAct Pharma AB

Latest news: SynAct Pharma AB

Last Transcript: SynAct Pharma AB

Analysts' recommendations: SynAct Pharma AB

Press Releases: SynAct Pharma AB

Quotes and Performance

Price Extremes

Managers and Directors: SynAct Pharma AB

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Quarterly revenue - Rate of surprise

Date	Insider	Type	Main position	Quantity	% Market Cap.
9/2/26	Jeppe Øvlesen	Sell	Founder	-150,000	0.2813%
9/2/26	Thomas Jonassen	Sell	Chief Technology Officer	-350,000	0.6563%
3/10/26	Anders Kronborg	Buy	Chairman	2,750	0.0052%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SYNACT PHARMA AB	+1.63%	+1.40%	-20.91%	+1.63%	97.08M
ELI LILLY AND COMPANY	-1.01%	+5.13%	+58.93%	+117.36%	1,144B
JOHNSON & JOHNSON	-0.61%	+1.52%	+34.34%	+68.48%	625B
ABBVIE INC.	-1.48%	+0.47%	+23.08%	+94.76%	511B
ROCHE HOLDING AG	+0.54%	+8.95%	+39.45%	+64.02%	377B
MERCK & CO., INC.	+1.07%	+1.70%	+71.06%	+45.98%	366B
NOVARTIS AG	+0.30%	+6.35%	+21.84%	+49.62%	291B
ASTRAZENECA PLC	-0.03%	+6.04%	+0.40%	+20.94%	262B
AMGEN INC.	-0.14%	+2.87%	+45.56%	+57.22%	237B
GILEAD SCIENCES, INC.	-1.88%	+0.02%	+23.77%	+97.39%	194B
Average	+0.13%	+5.66%	+29.75%	+61.74%	400.8B
Weighted average by Cap.	+0.33%	+6.91%	+40.78%	+79.56%

	2026 *	2027 *
Net sales	44.25M 4.47M 3.99M 3.69M 3.34M 6.29M 422M 6.37M 17.36M 222M 16.78M 16.43M 707M	21.6M 2.18M 1.95M 1.8M 1.63M 3.07M 206M 3.11M 8.48M 108M 8.19M 8.02M 345M
Net income	-47.08M -4.76M -4.24M -3.93M -3.55M -6.7M -449M -6.78M -18.48M -236M -17.86M -17.48M -752M	-31.92M -3.23M -2.88M -2.66M -2.41M -4.54M -305M -4.59M -12.52M -160M -12.11M -11.85M -510M
Net Debt	24.81M 2.51M 2.24M 2.07M 1.87M 3.53M 237M 3.57M 9.73M 124M 9.41M 9.21M 396M	74.22M 7.5M 6.69M 6.19M 5.6M 10.55M 708M 10.68M 29.12M 372M 28.15M 27.56M 1.19B